The 19 analysts offering 12-month price forecasts for Ultragenyx Pharmaceutical Inc have a median target of 75.00, with a high estimate of 90.00 and a low estimate of 48.00. The median estimate represents a +25.08% increase from the last price of 59.96.
The current consensus among 19 polled investment analysts is to Buy stock in Ultragenyx Pharmaceutical Inc. This rating has held steady since January, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.61
Reporting Date Feb 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.